Q1 EPS Estimates for Urogen Pharma Lifted by HC Wainwright

Urogen Pharma (NASDAQ:URGN) – Analysts at HC Wainwright upped their Q1 2026 earnings per share (EPS) estimates for shares of Urogen Pharma in a research note issued on Tuesday, March 3rd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.60) per share for the quarter, up from their prior forecast of ($0.63). The consensus estimate for Urogen Pharma’s current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for Urogen Pharma’s Q2 2026 earnings at ($0.64) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.99) EPS and FY2027 earnings at $0.45 EPS.

Several other analysts also recently weighed in on URGN. D. Boral Capital restated a “buy” rating and set a $33.00 price objective on shares of Urogen Pharma in a research report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, January 21st. Wall Street Zen upgraded shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Urogen Pharma in a report on Monday. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $33.29.

Urogen Pharma Stock Down 2.7%

Shares of URGN opened at $19.61 on Thursday. The stock has a 50 day moving average price of $20.94 and a 200 day moving average price of $20.86. The company has a market capitalization of $954.61 million, a price-to-earnings ratio of -6.13 and a beta of 1.34. Urogen Pharma has a 52-week low of $3.42 and a 52-week high of $30.00.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.12. The business had revenue of $37.84 million during the quarter, compared to analysts’ expectations of $39.92 million.

Institutional Trading of Urogen Pharma

Hedge funds have recently added to or reduced their stakes in the stock. Paradigm Biocapital Advisors LP grew its holdings in shares of Urogen Pharma by 6.1% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,473,648 shares of the company’s stock worth $104,773,000 after buying an additional 257,564 shares in the last quarter. Morgan Stanley boosted its position in Urogen Pharma by 1.4% during the fourth quarter. Morgan Stanley now owns 2,562,901 shares of the company’s stock worth $60,023,000 after acquiring an additional 34,455 shares during the last quarter. Soleus Capital Management L.P. purchased a new stake in Urogen Pharma in the 2nd quarter worth approximately $29,934,000. SG Americas Securities LLC grew its stake in Urogen Pharma by 19.0% in the 4th quarter. SG Americas Securities LLC now owns 1,377,647 shares of the company’s stock worth $32,264,000 after acquiring an additional 220,264 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Urogen Pharma in the 4th quarter worth approximately $26,350,000. 91.29% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Urogen Pharma

In other news, insider Mark Schoenberg sold 7,373 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total transaction of $145,174.37. Following the completion of the sale, the insider owned 144,985 shares in the company, valued at approximately $2,854,754.65. This represents a 4.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Jason Drew Smith sold 7,479 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $147,261.51. Following the transaction, the general counsel directly owned 51,326 shares in the company, valued at approximately $1,010,608.94. This represents a 12.72% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 4.70% of the company’s stock.

Urogen Pharma News Summary

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: Urogen’s quarterly report beat EPS expectations (smaller loss than forecast), prompting an early gap‑up in the shares as investors cheered the outcome. Read More.
• Positive Sentiment: D. Boral Capital assigned a “Buy” rating to URGN, which supports demand from investors looking for upside in the drug’s commercial rollout and can help short‑term sentiment. Read More.
• Neutral Sentiment: Coverage discusses UroGen weighing the commercial success of ENVISION and an expanded loan to support its bladder cancer push — this could fund growth but also increases leverage and execution risk, so the market reaction is ambiguous. Read More.
• Negative Sentiment: HC Wainwright substantially lowered near‑term EPS estimates: Q2 2026 to ($0.64) from ($0.42), Q3 2026 to ($0.42) from ($0.14), Q4 2026 to ($0.33) from $0.01, and cut FY2026 to ($1.99) from ($1.18). (They did slightly raise Q1 2026 to ($0.60) from ($0.63) and project FY2027 at $0.45.) These deeper downgrades to 2026 earnings signal weaker near‑term profitability expectations and are the main negative catalyst weighing on the stock. Read More.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.